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A B S T R A C T   
Finely-tuned gamma (FTG) oscillations can be recorded from cortex or the subthalamic nucleus (STN) in patients 
with Parkinson’s disease (PD) on dopaminergic medication, and have been associated with dyskinesias. When 
recorded during deep brain stimulation (DBS) on medication the FTG is entrained to half the stimulation fre-
quency. We investigated whether these characteristics are shared off medication by recording local field po-
tentials (LFP) from the STN from externalised DBS leads in 14 PD patients after overnight withdrawal of 
medication. FTG was induced de-novo by DBS in the absence of dyskinesias in a third of our cohort. The FTG 
could outlast stimulation or arise only after DBS ceased. FTG frequencies decreased during and across consec-
utive DBS blocks, but did not shift with changing stimulation frequency off medication. Together with the 
sustained after-effects this argues against simple entrainment by DBS in the off medication state. We also found 
significant coherence between STN-LFP and electroencephalogram (EEG) signals at FTG frequencies. We 
conclude that FTG is a network phenomenon that behaves differently in the off medication state, when it is 
neither associated with dyskinesias nor susceptible to entrainment.   
1. Introduction 
A finely-tuned gamma (FTG), occupying a narrow frequency band 
within the 60 and 90 Hz range, has been reported in the subthalamic 
nucleus, globus pallidus, thalamus and cortex in patients with various 
neurological disorders (Alegre et al., 2005; Alonso-Frech et al., 2006; 
Androulidakis et al., 2007; Brown et al., 2001; Foffani et al., 2005; 
Fogelson et al., 2006; Kempf et al., 2009; Litvak et al., 2012; Miocinovic 
et al., 2018; Swann et al., 2016). The FTG appears as a network oscil-
lation in so far as it is coherent between sites in the cortico-basal ganglia- 
thalamic loop (Brown et al., 2001; Fogelson et al., 2006; Kempf et al., 
2009; Litvak et al., 2012). In unexaggerated form it may be a primarily 
physiologic phenomenon related to arousal and voluntary movement, 
and its sharpness distinguishes it from canonical broadband gamma 
reactivity in the cortico-basal ganglia system (Jenkinson et al., 2013; 
Litvak et al., 2012). In patients with Parkinson’s disease (PD), FTG ap-
pears following medication with levodopa and is further increased 
during voluntary movements (Brown et al., 2001; Alonso-Frech et al., 
2006; Androulidakis et al., 2007), observations that have led it to be 
considered a prokinetic rhythm (Androulidakis et al., 2007; Brown, 
2003; Cassidy et al., 2002; Litvak et al., 2012). Hence, the extent of 
amplification of FTG during voluntary movement correlates positively 
with movement velocity in PD (Lofredi et al., 2018), although a broader 
gamma increase has also been linked to successful stopping of move-
ments (Fischer et al., 2017). Moreover, when excessively exaggerated, 
FTG in the basal ganglia thalamo-cortical loop may contribute to 
involuntary movements, such as levodopa-induced dyskinesias in PD 
(Swann et al., 2016), or dystonic posturing in isolated dystonia (Mio-
cinovic et al., 2018). The link to levodopa-induced dyskinesias has also 
been noted in animal models of Parkinsonism (Güttler et al., 2020). 
The generally prokinetic effect of FTG has led to speculation that it 
may mediate some of the effects of deep brain stimulation (DBS). Thus 
stimulating the subthalamic nucleus (STN) with individually detected 
FTG-frequencies can produce similar clinical benefit as stimulating with 
frequencies above 100 Hz (Tsang et al., 2012). Indeed, cortical FTG may 
shift in frequency to half that of DBS during stimulation of the STN, 
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signalling possible entrainment by stimulation when dyskinesias appear 
on medication (Swann et al., 2016). However, what happens to FTG 
during DBS when off medication or when dyskinesias are absent? Is it 
still affected by DBS, and if so in what way? Technical issues mean that, 
hitherto, it has been easiest to record LFP activity in the STN immedi-
ately after DBS to this target, and one study has reported that 60–90 Hz 
activity in the STN is not temporarily increased following STN-DBS 
performed off medication (Foffani et al., 2006). However, this study 
averaged gamma activity over patients with PD and as FTG is sharply 
tuned and inconsistent between patients, modulation may have been 
missed (Foffani et al., 2005). Another study managed to record FTG 
during DBS using high-density EEG and demonstrated a correlation 
between the power at FTG frequencies in both cortical regions and STN, 
which was derived using a beamformer algorithm, and local power at 
the stimulation frequency (Muthuraman et al., 2020). This occurred 
without a shift in the frequency of the presumed FTG activity, although 
the two stimulation frequencies used had subharmonics that were 
already close to the frequency of FTG. Moreover, this study reported co- 
modulation and did not directly demonstrate endogenous FTG. Here we 
explore whether STN-DBS off medication has an effect on local FTG 
activity allowing for the fact that this activity may only be recorded in a 
subset of patients (“high gamma” activity in López-Azcárate et al., 
2010). We address two major questions; is FTG in the STN promoted by 
DBS, appearing de-novo with stimulation, and if so is the new activity 
entrained by DBS? 
2. Materials and methods 
2.1. Consent, regulatory approvals and patient selection 
This protocol was approved by the Health Research Authority UK 
and the National Research Ethics Service local Research Ethics Com-
mittee (IRAS: 46576). Patients were recruited at St. George’s University 
Hospital NHS Foundation Trust, London. Written informed consent was 
obtained in line with the Declaration of the Principles of Helsinki. 
Fourteen patients with PD (1 female) undergoing bilateral STN-DBS 
surgery were included in the study. Their average age at the time of 
recording was 57.2 ± 1.6 years (mean ± SEM) with average disease 
duration of 10.1 ± 1.2 years. Three patients were recorded bilaterally, 
giving a total of 17 STNs included in the study. Clinical details are 
summarised in Table 1. Data from patients 1 to 9 and patients 11 and 12 
were previously published (Wiest et al., 2020). 
2.2. Clinical characterisation 
Study participants were evaluated by an interdisciplinary team of 
movement disorder neurologists and functional neurosurgeons and met 
the UK Parkinson’s Disease Society Brain Bank Diagnostic Criteria for 
diagnosis of PD (Hughes et al., 1992). Baseline motor function in the on 
and off medication state was characterised pre-operatively using part III 
of the Unified Parkinson’s disease Rating Scale motor subscale (UPDRS 
Table 1 
Patients clinical and recording details. Pre-OP: pre-operative; Post-OP: post-operative; UPDRS-III: Unified Parkinson’s disease Rating Scale (subunit III); FTG: finely- 
tuned gamma; Boston: Boston Scientific; Medt: Medtronic; STN (SP): superior-posterior part of the subthalamic nucleus; FOG: freezing of gait; STN/cZI: subthalamic 
nucleus/caudal Zona incerta; LID: levodopa-induced dyskinesia; RDRS: Rush Dyskinesia Rating Scale; DID: DBS-induced dyskinesia; n.a.: not applicable.  




















































Boston 4 R STN 
(SP) 
2 yes yes (6) no 
2 m 54 7 38 24 tremor Boston 5 R STN 
(SP) 
3.5 yes no (0) yes 




Boston 4 R STN/cZI 4 yes no (0) yes 
4 m 64 13 52 21 FOG, motor 
fluctuations 
Boston 4 R STN 
(SP) 
2 yes no (0) no 
5 m 53 7 23 12 Tremor Boston 4 R STN 
(SP) 
2 no no (0) no 
5 L STN 
(SP) 
3 yes no (0) no 
6 m 61 16 50 30 FOG, motor 
fluctuations 
Boston 3 L STN 
(SP) 
2 no no (0) no 
7 m 56 16 51 19 Rigidity, 
bradykinesia 
Medt 4 L STN 
(SP) 
4 no no (0) no 
8 m 65 5 34 16 FOG, motor 
fluctuations 
Boston 4 + 5 L STN/cZI 3 no yes (2) no 
4 R STN/cZI 2.5 no yes (3) yes 
9 f 63 11 40 17 FOG, motor 
fluctuations 
Boston 4 L STN 
(SP) 
2 no yes (2) no 
10 m 65 15 77 27 Akinetic-rigid, 
tremor 
Boston 5 L STN 
(SP) 
1.8 no yes (1) no 
11 m 61 9 33 12 Rigth arm 
tremor, 
bradykinesia 
Boston 4 L STN/cZI 4 no no (0) no 
12 m 48 8 45 34 Tremor, 
bradykinesia 
Boston 5 L STN/cZI 3 no no (0) no 
13 m 59 6 48 14 Akinetic-rigid Medt 5 R STN 
(SP) 
n.a. no yes (1) no 
14 m 53 7 18 1 Motor 
fluctuations,  
dyskinesia 
Boston 4 L STN/cZI 4 no no (0) no 
4 R STN/cZI 2.5 no yes (1) no  
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III). Patients were evaluated by a neuropsychologist to exclude signifi-
cant cognitive impairment or untreated affective disorders. During the 
recordings, an experienced neurologist was present to screen for 
dyskinesia. 
2.3. Surgery and lead localisation determination 
The surgical target was STN. Two models of DBS leads were used; 
either a quadripolar subthalamic lead (model 3389, Medtronic Inc., 
Neurological Division, USA) with four 0.5 mm spaced contacts of 1.5 
mm length with platinum‑iridium cylindrical surfaces or a directional 
subthalamic lead (model DB-2202, Boston Scientific, USA) with three 
segmented contacts on each of the middle two levels. These middle two 
levels sat above and below a concentric electrode contact. Electrodes 
were implanted using frame-based stereotaxy and MRI guidance. The 
subthalamic leads were connected to temporary extension leads and 
these externalised over the left temporal bone. Assessment of contact 
localisation was made through co-registration of immediate post- 
operative CT with pre-operative MRI by two experienced neurosur-
geons (E.A.P and A.M.) specialising in DBS. Assessment was blinded to 
the electrophysiological data and made using Renishaw Neuroinspire v6 
software. Localisation specifics are summarised in Table 1. 
2.4. Stimulation and data recording 
Recordings were made between 3 and 5 days postoperatively 
(Table 1), while electrode leads were still externalised and before im-
plantation of the subcutaneous pulse generator. All patients performed 
the experiments after overnight withdrawal of antiparkinsonian medi-
cation (Table 1). In patients with directional leads, the three directional 
contacts of level 1 and 2 were joined to form two ‘ring contacts’ so that 
each lead afforded four monopolar ring contacts. The four contacts were 
numbered E0 to E3 with contact E0 being the most ventral and contact 
E3 being the most dorsal (see Fig. 1A). Stimulation was only tested at the 
two middle contacts (E1 and E2) to allow bipolar LFP recordings from 
the two adjacent contacts. A self-adhesive electrode (Pals, Nidd Valley 
Medical Cordon, UK) attached to the patients’ back served as a reference 
for stimulation, which was delivered using a highly configurable neu-
rostimulator (Slater et al., 2015). Stimuli comprised symmetric 
constant-current biphasic pulses (60 μs per phase, negative phase first). 
In each of the two middle contacts, stimulation was started at 0.5 mA 
and slowly increased in steps of 0.5 mA every 3 to 4 min until first a clear 
benefit in rigidity and/or bradykinesia was observed and second side 
effects such as paraesthesia became apparent. The stimulation contact 
and current associated with the most clinically effective stimulation 
without side effects was selected and maintained throughout the entire 
experiment (DBS currents listed in Table 1). This procedure was per-
formed on the side contralateral to the most affected upper limb in 11 
subjects and bilaterally in 3 subjects (Table 1). If not indicated differ-
ently in the results, a stimulation frequency of 130 Hz was used. STN- 
LFPs were recorded in bipolar mode from the two contacts on either 
side of the stimulation contact, for common reference removal ((Schiff, 
Fig. 1. Stimulation settings and experimental paradigm. A. Schematic illustration of the electrode configuration. DBS was applied to one of the two middle contacts 
(E1 or E2) and LFPs were recorded bipolarly from the two adjacent contacts (E0 and E2 or E1 and E3). Bipolar contacts were recorded directly and not recovered off- 
line. B. Time-frequency spectrogram of first three DBS blocks in patient 1. During stimulation the finely-tuned gamma (FTG) arises (label 1) and then outlasts DBS 
(label 2) when it increases in frequency. In addition, beta suppression is evident during DBS (label 3). DBS blocks at 130 Hz are denoted by the grey bars at the top of 
the trace. Note that line noise artefacts were present throughout the recording at 50 Hz along with the DBS subharmonic at 65 Hz but are reduced by second-order IIR 
notch filters. C. DBS-induced narrowband artefacts at a subharmonic DBS frequency (65 Hz; label 4) or due to an aliasing phenomenon (80 Hz; label 5). Time- 
frequency spectrum shown for block 2 of patient 1with DBS at 130 Hz and before applying IIR notch filters (see Methods). The grey bar and vertical lines 
denote DBS onset and offset. The FTG feature is contoured (see Methods). Note that DBS-induced artefacts do not change in frequency throughout stimulation and 
cease immediately after DBS is stopped. D. Representative time-frequency spectrogram from patient 3 block 2. Apart from the FTG after DBS (label 6) we observe a 
low-gamma rebound (label 7) which appears after DBS is stopped with a slight delay, spans from 50 to 70 Hz and lasts for several seconds. 
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2005) and see Fig. 1A). Limited concomitant EEG electrodes were placed 
at Fz, FCz, Cz, Oz, C3, C4, CP3 and CP4 according to the extended 10–20 
EEG system and allowing at least a 3 cm distance from all incisions. EEG 
time series were recorded with a common average reference (that did 
not include LFP channels). All signals were amplified and sampled at 
2048 Hz using a TMSi Porti (TMS International, Netherlands) and 
custom-written software developed using the C programming language. 
The ground electrode was placed on the forearm. 
2.5. Experimental design 
During the experiments, patients were comfortably seated in an 
armchair. Note that recordings were performed using different experi-
mental protocols (some already published, see Wiest et al., 2020). Only a 
few patients were tested at different stimulation frequencies (patients 3, 
4, 8 and 9) and durations (patients 4, 5, 6 and 9). However, all re-
cordings started with two minutes of rest recording without stimulation 
(baseline) followed by blocks of continuous 130 Hz DBS. Stimulation 
blocks lasted for 163.1 ± 11.1 s (mean ± SEM) in up to four consecutive 
blocks separated by resting periods of on average 110.2 ± 9.9 s. Addi-
tional blocks with different DBS frequencies were tested in two of the 
five subjects showing the FTG (see Table 2). In patient 3, two blocks at 
70 Hz DBS (150.5 ± 1.4 s) were recorded followed by two blocks at 180 
Hz (153.5 ± 4.0 s), with resting periods of on average 118.9 ± 2.7 s 
between them. In patient 4, one DBS block at 180 Hz for 24.0 s and 
another block at 190 Hz for 24.1 s separated by a series of short DBS 
bursts at the same frequency (25 bursts of on average 115.2 pulses at 
180 Hz and 15 bursts of on average 143.5 pulses at 190 Hz; Fig. 5B) were 
recorded. Also in patient 4, four short duration DBS blocks (13.1 ± 0.2 s) 
were recorded at 70 Hz, 130 Hz and 190 Hz each (see Table 2), each 
separated by resting periods of on average 149.0 ± 3.9 s. 
2.6. Signal processing: pre-processing 
All data analysis was performed using custom-written scripts in 
MATLAB (version 2019a, Mathworks, Massachusetts, USA). Continuous 
LFP signals were linearly de-trended to remove low-frequency drifts 
using MATLAB’s detrend function and DBS artefacts were removed by 
applying second-order IIR notch filters (Q-factor = 200; see Fig. 1B). 
These artefacts include line noise at 50 Hz (all recordings), a peak at the 
subharmonic frequency of 65 Hz during stimulation at 130 Hz in 11/17 
STNs (and all 5 patients displaying FTG), and a narrowband signal that 
appeared at 80 Hz in 8/17 STNs (Fig. 1C; only patients 1 and 2 dis-
playing FTG). The narrowband character of these signals and the fact 
that they were not delayed in onset and did not outlast the DBS blocks or 
change in frequency over time differentiated them from the FTG. 
Spectral amplitudes were estimated between 65 and 90 Hz using the 
short-time Fast Fourier transform with a window length of 1 s, 25% 
overlap of consecutive windows and a Hamming window as imple-
mented in MATLAB’s spectrogram function yielding a frequency resolu-
tion of 1 Hz. 
2.7. Signal processing: FTG detection 
We restricted our search for the FTG to the frequency range from 65 
to 90 Hz (Kempf et al., 2009; Swann et al., 2016) to avoid DBS sub-
harmonics (only DBS stimulation frequencies of 70, 130, 180 and 190 Hz 
were used across patients). The presence of FTG was assessed in each 
STN and stimulation block by visual inspection of both the time- 
frequency spectrograms and power spectral densities (PSD). To this 
end, PSDs were computed in three time windows. First, a baseline PSD 
was computed in a 50-s window before each DBS block (− 52 s to − 2 s; to 
avoid contamination from artefacts when DBS was switched on). Sec-
ond, PSDs were computed during stimulation and finally, post-DBS PSDs 
were computed in a 5-s window after DBS was switched off. This win-
dow length was selected based on visual inspection of the time- 
frequency maps to include short lasting FTGs persisting after DBS. The 
PSD from all four epochs was flattened using a fourth order polynomial 
(detrend function) to correct for the 1/f pattern (Pritchard, 1992) and z- 
scored (Swann et al., 2016). The presence of FTG was determined by the 
presence of a peak between 65 and 90 Hz that was over two standard 
deviations above the average of the respective time window using 
MATLAB’s findpeaks function (MinPeakHeight: 2) and confirmed by 
visual inspection of the time-frequency maps. This approach was effec-
tive even in 10-s windows if the FTG is present and allows to track the 
FTG peak during and after DBS (Supplementary Video 1). 
Table 2 
Details of the finely-tuned gamma. Electroencephalogram (EEG) contacts are labelled according to the extended 10–20 EEG system at Fz, FCz, Cz, Oz, C3, C4, CP3 and 
CP4. FTG duration, amplitude and frequency were extracted using a cluster based approach (see Methods). Freq.: frequency; R: right; L: left; n.a.: not applicable.  





































notes EEG channel of  
greatest 
coherence 






74 [73–75]  during R DBS: C3 
2 3 130 no n.a. n.a. yes 16.3 
[14.3–20.3] 
77 [77–77]  after (5 s) R DBS: 
C3 
3 9 4 × 130 
3 × 180 







82 [82–82] 70 Hz: no FTG 
130 and 180 Hz: FTG 
during and after DBS 
during R 130 Hz: 
FCz 
after R 130 Hz: 
C4 
during R 180 Hz: 
CP4 
after R 180 Hz: 
Fz 
4 5 (long) 
12 (short) 
long: 3 × 130, 1 
× 190, 1 × 180 
short: 4 × 70, 4 
× 130, 4 × 190 




70 Hz: no FTG 
130 Hz: FTG after 
DBS 
190 Hz: FTG during 
and after DBS 
after R 130 Hz: 
CP4 
during R 180 +
190 Hz: CP3 
after R 190 Hz: 
CP4 
5 4 (long) 
5 (short) 




no n.a. n.a.  during L blocks: 
Fz  
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2.8. Signal processing: FTG amplitude and frequency evolution during 
DBS 
In subjects that showed an FTG in the PSD and time-frequency plot 
during DBS (see Table 2), the amplitude and frequency profiles of the 
FTG were further characterised. To this end, we first defined a more 
constrained region of interest (ROI) in the time-frequency domain. The 
frequency-axis of the ROI was determined based on the largest PSD peak 
during the whole DBS block (signal flattened and z-scored as described 
above) ± 5 Hz. The time-axis equalled the block duration. Further, 
power estimates within the ROI were binarised. All power estimates that 
were equal to or above the 70th percentile of all power estimates in the 
ROI were given the value 1 and all remaining power estimates the value 
0. Clusters of connected pixels of value 1 were identified using MAT-
LAB’s bwconncomp function (8-connected mode; pixels are connected if 
their edges or corners touch). Note that each estimate corresponds to 1 
Hz × 0.75 s (ROI size: 11 Hz x DBS duration in bins of 0.75 s), except in 
patient 5 where the ROI was changed to 14 Hz x DBS duration*0.25 
since the FTG feature was only present in the first quarter of the block 
and it was further spread along the frequency axis (average ROI size 
1666.5 ± 234.1 power estimates). Clusters consisting of less than 15 
individual power estimates were removed from the cluster map to 
exclude possible random fluctuations. All clusters that survived this 
selection were considered as components of the FTG (see Fig. 3A). 
Frequencies and amplitudes of the FTG were determined for each time 
bin (0.75 s, based on settings of the frequency decomposition) for the 
power estimate with the highest activity within the cluster. To quantify 
FTG features during and after DBS (Figs. 3 and 4), average FTG fre-
quency and amplitude profiles per subject (mean of all blocks) were z- 




where FTGS represents the average FTG feature per subject (mean of all 
blocks) and FTGZ the z-scored FTG feature. 
2.9. Signal processing: FTG duration, amplitude and frequency evolution 
after DBS 
In subjects that showed an FTG after DBS in the PSD and time- 
frequency plot, we used a similar method to the above to precisely 
define the frequency and amplitude profiles of the FTG activity. Dif-
ferences from the procedure above were as follows. The frequency-axis 
of the ROI was based on the post-DBS PSD peak and the time-axis was set 
to 30 s (60 s in subject 3) based on visual inspection (average ROI size: 
641.7 ± 67.2 power estimates). Only the largest cluster was kept to 
define FTG duration, amplitude and frequency. FTG duration was 
defined as the length of the FTG cluster following cessation of DBS (see 
Fig. 4A). 
2.10. Signal processing: LFP-EEG coherence analysis 
In all subjects with significant FTG peaks in the power spectrum we 
computed coherence between the STN-LFP and EEG. EEG signals were 
linearly de-trended and data from consecutive DBS blocks were 
concatenated within subjects. Coherence analysis was performed on 
unfiltered data. Magnitude-squared coherence was computed using the 
short-time Fast Fourier Transform with window length 0.5 s and 0% 







where Pxx(f) and Pyy(f) correspond to the power spectral densities and 
Pxy(f) to the cross power spectral density. Significance levels of 
coherence were assessed using an upper 95% confidence limit based on 
the assumption of independence; for details see (Halliday et al., 1995). 
The EEG channel with greatest coherence per subject is shown in Table 2 
and Fig. 7. To compute coherence after DBS blocks, 5-s windows after 
the last stimulation artefact were concatenated within subjects. EEG-LFP 
coherence was considered to be present when it exceeded the upper 95% 
confidence limit at the same frequency as the corresponding FTG in the 
STN-LFP. 
2.11. Statistics 
Statistical analyses were conducted using custom-written scripts in 
MATLAB. Comparisons of the FTG features (duration, frequency and 
amplitude) between the start and end of the stimulation blocks were 
performed using linear mixed-effects models on individual data. The 
FTG features were set as dependent variables (raw features) and the first 
and last 5-s time windows as fixed effects. A similar approach was used 
to compare the FTG features across consecutive blocks. The normal 
distribution of each variable and the residuals were visually inspected 
with quantile-quantile plots and histograms of distribution. All models 
were estimated by the method of maximum likelihood and included 
random intercept for subjects to allow different intercepts for each 
subject, thereby capturing individual differences. Linear mixed-effects 
models allow for missing data and comparisons of small sample sizes 
(Muth et al., 2016). 
3. Results 
3.1. FTG can be induced by DBS off medication 
Five of 14 patients (35.7%) revealed FTG activity either during or 
after DBS following overnight withdrawal of antiparkinsonian medica-
tion (see Table 1 and significant peaks in PSD of Fig. 2). The FTG arose 
de-novo as it was not discernible during a 50-s baseline period prior to 
DBS start (Fig. 2). During continuous stimulation at 130 Hz, FTG was 
observed in the spectrogram of 3 patients (cases 1, 3 and 5) with at least 
a few seconds delay from stimulation onset (Fig. 2A, C and E). Case 4 
displayed an FTG during stimulation at 180 and 190 Hz, and will be 
considered separately, later. 
After DBS, FTG was observed in four patients and changed in pattern. 
In two patients the FTG outlasted DBS (patient 1 and 3; Fig. 2A+C), 
whereas in the other two it only started after DBS ceased (patient 2 and 
4; see Fig. 2B+D). In 4 of 5 patients that displayed any FTG we observed 
an additional broad low-gamma rebound after stimulation was stopped 
(Fig. 1D), as seen in an earlier study (Wiest et al., 2020). This activity 
spanned from 40 to 70 Hz. Its broadband character and lower frequency 
range helped to differentiate it from the FTG. 
No dyskinesias were reported during or after stimulation in the 
subjects with FTG (Unified Dyskinesia Rating Scale Part III = 0, (Goetz 
et al., 2008)), suggesting that FTG can be observed in PD patients off 
medication without dyskinesia. 
3.2. FTG dynamics during DBS 
FTG dynamics were further explored during stimulation in patients 
1, 3 and 5. As can be observed in Fig. 2, during 130 Hz DBS, the FTG 
varied between patients. However, in all three the FTG began only after 
a few seconds of stimulation and demonstrated an initial drop in fre-
quency during the first 20s of stimulation (Fig. 2A, C and E). To better 
describe the modulation of the FTG in time, we first identified the FTG in 
the spectral domain using a cluster-based approach (see Methods and 
Fig. 3A). Subsequently, we extracted duration, frequency and amplitude 
over time from the identified cluster. On average, the FTG lasted for 
77.6 ± 13.5 s (47.8 ± 8.2% of the time during DBS; all blocks of patients 
1, 3 and 5 included) with a high inter- and intra-subject variability (see 
Table 2). The averaged FTG frequency profile suggests a decrease with 
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stimulation duration (Fig. 3C and Supplementary Video 1) which was 
significant when comparing the average frequency of the first and last 5 
s of the FTG in all blocks of all 3 patients (LME: b = − 2.6, t = − 5.2, p <
0.001; Fig. 3D). In contrast, there was no significant difference between 
the initial and final FTG amplitude (LME: b = − 0.02, t = − 0.7, p = 0.47; 
Fig. 3G). 
To differentiate the FTG from a broadband gamma increase during 
DBS, we computed relative changes of power estimates with respect to a 
Fig. 2. 130 Hz DBS induces finely-tuned gamma (FTG) oscillations in the absence of levodopa and dyskinesia. A-E. Left: time-frequency spectrograms of repre-
sentative DBS blocks. The grey bar on top of the trace and the vertical dashed lines denote DBS onset and offset. The FTG feature is surrounded by a contour in each 
case (based on a 70th percentile threshold of a ROI, see definition in methods section and Fig. 3A). Right: Power spectral densities (PSD) during a 50-s baseline period 
before DBS onset, during the DBS block and during a 5-s window after DBS cessation, with the exception of case 5 (E) in whom the spectrum of a narrower region of 
interest (win; 20 s long) is presented. The grey horizontal line denotes the FTG threshold at 2 standard deviations above average baseline. Peaks above the threshold 
are considered significant (black arrowheads). This analysis was confirmed by visual inspection. 
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50-s baseline period before DBS onset. Power estimate changes of pa-
tients 1, 3 and 5 were averaged across 4  DBS blocks each. The FTG 
feature showed a greater power increase than adjacent frequencies in 
the gamma band (Supplementary Fig. 1). Hence, FTG induction is se-
lective and not accompanied by a broadband DBS-induced gamma 
event-related synchronisation (ERS). 
All three patients showing FTG during DBS performed four consec-
utive blocks at 130 Hz, allowing us to assess FTG dynamics across 
consecutive DBS blocks. Linear mixed-effects models revealed a 
significant reduction of the average FTG frequency across DBS blocks 
(LME: b = − 0.72, t = − 4.7, p < 0.001; Fig. 3E), but no change in average 
FTG amplitude (LME: b = 0.01, t = 0.6, p = 0.56; Fig. 3H) or FTG 
duration during DBS across blocks (LME: b = 5.89, t = 1.85, p = 0.09; 
Fig. 3B). 
3.3. FTG dynamics after DBS 
After discontinuation of 130 Hz DBS, the FTG lasted on average 23.2 
Fig. 3. FTG dynamics during DBS blocks. A. Time-frequency spectrogram of a representative DBS block from patient 1. The grey bar and vertical dotted lines denote 
DBS onset and offset. The black contour surrounds power estimates above the 70th percentile of the ROI (see Methods). B. FTG durations during DBS in percentage of 
the total length of the stimulation block (linear mixed-effects model (LME): b = 5.89, t = 1.85, p = 0.09). C. FTG frequency during DBS over time averaged across 
blocks for each patient (data z-scored to frequencies during DBS; n = 3). Note the different FTG durations during DBS. Group average in black only given when data 
from all 3 patients was available. D. FTG frequency decreases between the first and last 5 s of a DBS block (LME: b = − 2.6, t = − 5.2, p < 0.001). Big dots denote 
averages of patients, small dots denote single blocks. Patients colour coded as in B. E. Mean FTG frequencies decreased across consecutive DBS blocks (LME: b =
− 0.72, t = − 4.7, p < 0.001). F. FTG amplitude during DBS over time (data z-scored to amplitudes during DBS; n = 3). G. FTG amplitude in the first and final 5 s of a 
DBS block (LME: b = − 0.02, t = − 0.7, p = 0.47). Big dots denote averages of patients, small dots denote single blocks. H. Average FTG amplitude does not change 
across consecutive DBS blocks (LME: b = 0.01, t = 0.6, p = 0.56). 
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± 4.1 s (Fig. 4C and Table 2). There was no significant difference in 
frequency between the first and last 5 s (LME: b = 0.82, t = 1.6, p = 0.12; 
Fig. 4D). However, post-DBS FTG frequencies appeared to be very var-
iable across patients. While patients 3 and 4 displayed an almost U- 
shaped frequency curve, FTG frequencies tended to increase in patient 1 
and decrease in patient 2. In contrast, the FTG amplitude after DBS 
decreased (Fig. 4F), with a significant difference when comparing am-
plitudes between the first and last 5 s (LME: b = − 0.15, t = − 5.2, p <
0.001; Fig. 4G). Across consecutive blocks, no trends or significant dif-
ferences were observed in FTG duration (LME: b = − 5.26, t = − 1.59, p 
= 0.15; Fig. 4B), maximal FTG amplitude (LME: b = − 0.03, t = − 0.76, p 
= 0.46; Fig. 4H) and average FTG frequency (LME: b = − 0.01, t =
Fig. 4. FTG dynamics after DBS blocks A. Representative time-frequency spectrogram of FTG after DBS termination in patient 3. Vertical dashed line denotes the DBS 
offset and the scale shows FTG duration. The black contour surrounds power estimates above the 70th percentile of the ROI (see Methods). B. FTG duration across 
blocks. Linear mixed-effects models do not show a significant change (LME: b = − 5.26, t = − 1.59, p = 0.15; only first 3 blocks included). C. FTG frequency after DBS 
over time averaged across blocks for each patient (data z-scored to FTG frequencies after DBS; n = 4). Note the different FTG durations after DBS. Group average in 
black only given when data from all 4 patients was available. D. FTG frequencies after DBS do not differ between the first and last 5 s (LME: b = 0.82, t = 1.6, p =
0.12). Patients are colour coded as in C. E. Average FTG frequencies across blocks (LME: b = − 0.01, t = − 0.04, p = 0.94; only first 3 blocks included). F. FTG 
amplitude after DBS over time averaged across blocks for each patient (data z-scored to FTG amplitudes after DBS; n = 4). G. FTG amplitude decreases between the 
first and last 5 s of the post-DBS FTG (LME, b = − 0.15, t = − 5.2, p < 0.001). H. Maximal FTG amplitudes do not change across consecutive DBS blocks (LME: b =
− 0.03, t = − 0.76, p = 0.46; only first 3 blocks included). 
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− 0.04, p = 0.97; Fig. 4E). Note that only the first 3  DBS blocks were 
included as it was the minimum number of repetitions performed across 
the 4 patients showing post-DBS FTG. These results suggest that the FTG 
appears to be consistent after multiple DBS blocks in individual patients. 
3.4. FTG frequency does not change with different DBS frequencies off 
medication 
In two patients that displayed FTG during or after 130 Hz DBS, we 
tested if different DBS frequencies elicited changes in FTG peak fre-
quency, suggestive of entrainment. In patient 3, DBS was tested at 70 Hz 
and 180 Hz, as well as the standard 130 Hz. Stimulation at 70 Hz did not 
induce an FTG, however, we cannot preclude the presence of an FTG 
feature underneath the stimulation artefact or its subharmonics. Stim-
ulation at 180 Hz led to an FTG at about 80 Hz, similar to the FTG eli-
cited by DBS at 130 Hz (compare Fig. 5A with Fig. 2C and 
Supplementary Video 1). In contrast to the artefact at 80 Hz (Fig. 1C), 
this 80 Hz-signal started with a delay after DBS onset and outlasted 
stimulation. Moreover, it showed dynamic changes and was hence 
considered as an FTG feature. In patient 4, DBS was delivered at 180 Hz 
and at 190 Hz separated by short stimulation bursts consisting of re-
petitive periods on and off DBS at these frequencies (Fig. 5B). While DBS 
at 130 Hz only elicited an FTG after DBS in this patient (Fig. 2D), DBS at 
180 Hz and 190 Hz induced a significant FTG peak during stimulation 
which outlasted DBS. FTG frequency was at about 80 Hz for all three 
DBS frequencies (compare Fig. 5B and Fig. 2D). While the patients and 
block numbers are too small to make definitive inferences, two trends 
are apparent: Firstly, FTG frequencies remained reasonably constant 
during and after DBS at different driving frequencies (Fig. 5C+D) and, 
secondly, FTG amplitudes during DBS seemed to increase with DBS 
frequency (Fig. 5E) while FTG amplitude after DBS was similar at 130, 
180 and 190 Hz stimulation (Fig. 5F). The latter is underpinned by the 
results observed in short blocks of DBS (four blocks per DBS frequency of 
on average 13.1 ± 0.2 s) at 70 Hz, 130 Hz and 190 Hz in patient 4. While 
Fig. 5. Different DBS frequencies do not change FTG frequency A. Left: Time-frequency spectrogram of representative DBS block. Grey bars above the spectrogram 
and the vertical dashed lines denote DBS onset and offset. Different DBS frequencies are shown in the grey bars. The black contour surrounds the FTG feature within 
the ROI (see Methods). PSD shown for the first and second half during DBS and the 5-s reference period after DBS cessation. Grey horizontal line denote the FTG 
threshold at two standard deviations above average of the respective reference periods. Black arrowheads denote significant PSD peaks. B. Left: Time-frequency 
spectrogram of DBS at 180 and 190 Hz. Both DBS blocks are separated by DBS bursts (label: DBS bursts) consisting of repetitive periods on and off DBS of vari-
able length. Right: PSD shown for periods during DBS at 180 and 190 Hz and a 5-s reference after DBS ceased. Horizontal line, contours and arrowheads as in A. C +
D. FTG frequencies during (C) and after (D) long DBS blocks plotted over DBS frequencies at 130 Hz, 180 Hz and 190 Hz (all blocks from patients 3 and 4). Despite 
varying DBS frequencies, the FTG stays at a similar frequency. E + F. FTG amplitudes during (E) and after (F) long DBS blocks plotted over DBS frequencies at 130 Hz, 
180 Hz and 190 Hz (all blocks from patients 3 and 4). During DBS, FTG amplitudes tend to be increased at higher driving frequencies. 
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DBS at 70 Hz and 130 Hz did not induce an FTG meeting our criteria 
either during or after DBS, 190 Hz stimulation triggered an FTG during 
short blocks (Fig. 6A). In patient 5, the FTG was evident in short blocks 
of on average 22.4 ± 1.2 s even at 130 Hz (Fig. 6B) with a similar profile 
as in long blocks but cut short by DBS termination. 
3.5. LFP-EEG coherence at FTG frequencies 
Since the FTG has previously been detected in cortical recordings we 
studied LFP-EEG coherence. We found significant LFP-EEG coherence at 
FTG frequencies in all the patients exhibiting FTG in their STN-LFP 
(Fig. 7 and Table 2). Based on patients 3 and 4, coherence tended to 
be greater at higher DBS frequencies (Fig. 7C+D) similar to the 
increased FTG amplitude during blocks of increased DBS frequencies. 
4. Discussion 
In this study, we show that STN-DBS induces FTG in the STN-LFP of 
about a third of patients after overnight withdrawal of antiparkinsonian 
medication. As previously reported, we also found significant coherence 
at FTG frequencies between the STN-LFP and EEG. However, unlike the 
FTG described in PD patients on dopaminergic medication, we recorded 
FTG while dyskinesias were absent. Furthermore, there was no evidence 
to suggest a shifting of the FTG frequency in the STN according to 
stimulation frequency off medication, and FTG could be maintained for 
~20 s after DBS. These observations suggest that off medication the FTG 
was not entrained by DBS, although we did find that FTG frequencies 
subtly, but significantly, declined within and across consecutive DBS 
blocks. 
4.1. Was FTG induced or entrained by DBS? 
Swann et al. (2016 and 2018) previously demonstrated that the FTG 
recorded at the cortical level in PD patients on medication may be 
entrained by high frequency stimulation of the STN when patients 
experience dyskinesia. This entrainment was manifest as a shift in the 
frequency of the FTG peak to that of the subharmonic of the stimulation 
frequency. Another study reported a correlation between power at FTG 
frequencies in STN and cortex and local power at the stimulation fre-
quency (Muthuraman et al., 2020). However, this study could not 
establish entrainment through a shifting of FTG frequency to match 
subharmonics of the stimulation frequency, and did not directly 
demonstrate endogenous FTG at the stimulation sites during stimulation 
in the off medication state. In the current study, also off medication, we 
were able to record de-novo FTG, and demonstrate that it outlasted 
stimulation by on average 20s, or even appeared for the first time during 
this period. These relatively sustained stimulation after-effects in addi-
tion to the stability of FTG frequencies independent of the DBS fre-
quency argue against simple entrainment of the FTG by DBS. 
The lack of evidence of shifts in FTG frequency (or in LFP-EEG 
coherence) with different stimulation frequencies would also be 
against direct entrainment of FTG. Here, however, some caution is 
required. We recorded both a stereotyped frequency FTG in the power 
spectra density during stimulation, and signal at stimulation sub-
harmonics. Totally discounting a physiological contribution to those 
subharmonics is difficult, although their narrow, fixed frequency and 
their duration precisely matching the duration of stimulation might 
point more to stimulus artefact. Also of note, the LFP-EEG coherence 
during DBS only disclosed a peak at the same frequency as the FTG in 
corresponding power spectra of the LFP and not at half the stimulation 
frequency in patients 1, 4 and 5 (Fig. 7). 
In summary, the evidence argues against entrainment of the FTG by 
DBS off medication and is more in favour of the inducing of FTG as 
stimulation reconfigures networks to support this oscillation, perhaps 
paralleling how levodopa reconfigures networks to induce FTG (Jen-
kinson et al., 2013). Interestingly, the duration over which FTG 
Fig. 6. FTG in short DBS blocks. A. In patient 4, short DBS blocks of on average 13.1 ± 0.2 s (separated by resting periods of 149.0 ± 3.9 s) were tested at different 
DBS frequencies. The grey bars and vertical lines denote DBS onset and offset. DBS frequencies are shown in the boxes. Every frequency was tested four times (only 
one block shown for 70 and 130 Hz). Note the notch filter at 70 Hz when stimulation was at 70 Hz. Colour bar as in Fig. 6A. The FTG feature is surrounded by a 
contour where present. B. In patient 5, short DBS blocks of on average 22.4 ± 1.2 s (separated by resting periods of 177.2 ± 18.6 s) were tested at 130 Hz. The grey 
bars and vertical lines denote DBS onset and offset. Colour bar as in Fig. 6A. The FTG feature is surrounded by a contour. 
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outlasted stimulation is similar to the time beta oscillations take to re-
turn to pre-stimulation levels (Wiest et al., 2020), and corresponds to the 
delayed recovery of bradykinesia after cessation of DBS (Kühn et al., 
2009). 
Why might STN-DBS entrain FTG when patients are dyskinetic on 
medication in the case of the study by Swann et al. (2016), but not when 
not dyskinetic off medication, as here? The former study sampled FTG 
from sensorimotor cortex, but this is unlikely to be responsible for the 
difference given that STN and cortical activities are coherent at FTG 
frequencies as reported previously (Brown et al., 2001; Cassidy et al., 
2002; Litvak et al., 2012; Williams et al., 2002) and confirmed here. 
Perhaps more likely the difference arises from the effects of dopami-
nergic therapy. When this medication is withdrawn overnight, sponta-
neous FTG in the STN is absent or diminished (Jenkinson et al., 2013), 
and when induced by stimulation FTG does not shift in frequency ac-
cording to the frequency of stimulation. On dopaminergic medication 
Fig. 7. LFP-EEG coherence at FTG frequencies. A.-E. EEG channel with greatest coherence is shown for all FTG subjects. For during blocks analysis, time series were 
concatenated within subjects. For after block analysis, signals in a 5-s time window following cessation of DBS were concatenated within subjects. In patient 4 and 5 
short and long DBS blocks were concatenated together. If not 130 Hz, DBS frequencies are shown on top of the plots. EEG channels are colour coded. Black horizontal 
line denotes the significance level (see Methods). Black arrowheads indicate the corresponding frequency of the FTG peak in the STN-LFP power spectrum. Coherence 
at FTG frequency was significant in all subjects shown. Note that artefactual coherence is variously seen at 50 Hz (line noise), 65 Hz (subharmonic of 130 Hz DBS) 
and 90 Hz (subharmonic of 180 Hz DBS). 
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FTG is exaggerated and sharply tuned (in those recordings displaying 
such activity), suggesting an under-damped oscillation that is more 
likely to be subject to resonance-related phenomena like amplitude 
enhancement and entrainment by driving frequencies, or subharmonics 
thereof, that are relatively closely related in frequency. In summary, 
although off medication DBS may induce, but not entrain, FTG, the 
situation may be different on medication. 
4.2. Why is the FTG an inconsistent finding across patients? 
Only about a third of patients had an FTG induced by stimulation. 
One explanation might be that the FTG was obscured by a broadband 
power suppression during DBS in many patients. However, this is un-
likely given that power suppression is only significant in the beta and 
low-gamma range (Wiest et al., 2020). Another explanation might be 
that patients without FTG were under-stimulated. However, stimulation 
amplitudes ranged from 1.8–4 mA in both FTG and non-FTG subjects 
(Table 1). Instead, it is possible that the factors determining the presence 
or absence of FTG during or immediately after stimulation might be 
similar to those determining the presence or absence of FTG in patients 
on medication, where a similar proportion of patients display FTG 
(López-Azcárate et al., 2010). While the FTG can be detected in a widely 
distributed network, including thalamus, internal segment of the globus 
pallidus, STN and cortex, within these sites it may be highly focal. In the 
STN, in particular, FTG arises within the dorsolateral STN and adjacent 
Zona incerta (Lofredi et al., 2018; Trottenberg et al., 2006), raising the 
possibility that minor differences in electrode placement may account 
for the presence or absence of FTG within our, and other, cohorts. These 
differences, if they exist, were too small to be picked up by the imaging 
co-registration techniques in our limited sample (see Table 1). It could 
also be that the processes supporting gamma synchrony are susceptible 
to the stun effect of surgery, but chronic recordings in the same patients 
will be necessary to establish this. Finally, there might be phenotypic 
differences that determine the presence of FTG. Of these, the propensity 
for dyskinesias has received the most interest (Alonso-Frech et al., 2006; 
Fogelson et al., 2005; Swann et al., 2016). The induced FTG lasted 10s of 
seconds following the cessation of stimulation which mirrors the time 
necessary for DBS-induced dyskinesias to subside. However, we studied 
patients in the off medication state, without dyskinesias. The FTG 
therefore does not seem to be exclusively linked to dyskinesias (see 
Table 1) as it has also been shown in invasive recordings from patients 
suffering from dystonia and myoclonus epilepsy at rest (Kempf et al., 
2009). At best therefore, the FTG induced by stimulation in the off 
medication state may be a trait marker of the propensity for dyskinesias, 
even if on medication it may be more directly involved in the generation 
of these involuntary movements (Swann et al., 2016; Swann et al., 
2018). 
4.3. Study limitations 
Our study has a relatively low sample size of 14 patients (17 STNs), 
with only a minority of these showing an induced FTG. Although we 
used linear mixed-effects models which allow for comparisons of small 
sample sizes (Muth et al., 2016), we acknowledge that our results should 
be interpreted carefully and require corroboration in a larger sample. In 
addition, recordings shortly after DBS surgery may be confounded by 
transient symptom alleviation and circuit disruption due to electrode 
implantation (Chen et al., 2006; Mann et al., 2009). 
5. Conclusions 
We report FTG oscillations that arise de-novo during or immediately 
after STN-DBS in the off-medication state, which can be seen in the STN- 
LFP and in the coherence between this and EEG. The response to 
different stimulation frequencies and the prolonged stimulation after- 
effects suggest that in the off medication state the FTG is induced 
rather than entrained, providing evidence of a stimulation-related 
reconfiguration of basal ganglia circuits to support gamma oscilla-
tions. The presence of slow changes in FTG frequency within and across 
consecutive DBS blocks suggests that such circuit reconfiguration may 
itself subtly evolve over time. 
Supplementary data to this article can be found online at https://doi. 
org/10.1016/j.nbd.2021.105287. 
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